85 results about "Drug encapsulation" patented technology

The invention relates to double-encapsulated lipid nanoparticles entering brain through nose and a preparation method and application thereof, the double-encapsulated lipid nanoparticles comprise lipid nanoparticles, drugs in the lipid nanoparticles and rana odorata lectin coupled to the surfaces of the lipid nanoparticles, and the drugs comprise hydrophilic drugs and hydrophobic drugs. According to the invention, the rana odorata lectin and the lipid nanoparticles are coupled, and the rana odorata lectin can be specifically combined with L-fucose residues expressed by olfactory epithelial cells, so that the adhesion of the lipid nanoparticles to olfactory epithelium during nasal administration is enhanced, and the brain entering efficiency of the lipid nanoparticles is finally improved. After entering the brain, the lipid nanoparticles respond to diseased regions with high active oxygen content so as to release drugs. In addition, double-drug encapsulation can target different pathogenesis of central nervous system diseases, and the limitation that a traditional treatment drug is single in action target is improved.

The method comprises the following steps: dissolving lipoic acid and a drug in an organic solvent to form a homogeneous solution, dropwise adding deionized water while stirring, then adding a reducing agent, initiating lipoic acid polymerization and drug co-assembly in situ at 20-40 DEG C to form a drug-loaded micelle solution, and carrying out freeze drying on the drug-loaded micelle solution to obtain the nano-preparation drug based on polylipoic acid. And dialyzing and purifying to obtain the nano preparation medicine based on polylipoic acid. The preparation method is characterized in that lipoic acid has dual characteristics of a drug carrier matrix and a dynamic crosslinking monomer, carrier synthesis and efficient drug encapsulation are synchronously realized through one-step in-situ polymerization-co-assembly, and the technical bottleneck that a traditional nano-carrier needs pre-synthesis and step-by-step drug loading is broken through. The method has the following practicability: (1) the process is simple and efficient, complex equipment is not needed, and reaction conditions are mild; (2) the drug loading performance is excellent, and the particle size is uniform and adjustable (50-300 nanometers); (3) a polylipoic acid skeleton endows the nano-drug preparation with environmental responsiveness, and intelligent drug release can be realized; and (4) the method is suitable for hydrophobic drugs and compound preparations. The method provides a high-load, high-stability and stimuli-responsive nanocrystallization solution for hydrophobic drug delivery, and has application value in the field of nano-medicines.

The invention discloses a preparation method of polymer drug-loaded nanoparticles. According to the method, on the basis of an emulsification method, the controllable continuous preparation of the polymer drug-loaded nanoparticles is realized by utilizing an ultrasonic micro-fluidic technology. The method specifically comprises the following steps: dissolving a drug and a polymer in a water-insoluble organic solvent to serve as an organic phase, taking a surfactant aqueous solution as a water phase, introducing the two phases into ultrasonic microfluidic equipment at a certain flow velocity ratio, and emulsifying under the ultrasonic action to obtain uniform liquid drops; and removing the organic solvent by methods of stirring, rotary evaporation, vacuum centrifugation, ultrafiltration and the like to obtain the cured polymer drug-loaded nanoparticles. The nanoparticles prepared by the method are uniform in particle size and high in drug encapsulation efficiency, and can be continuously produced.

This invention discloses a polymer-loaded drug-eluting nanoparticle with high encapsulation efficiency and its application in coatings and surface film materials. The polymer-loaded drug-eluting nanoparticles are prepared via emulsion polymerization, simultaneously loading antibacterial drugs with different log P values. The preparation process is simple, and the resulting product has small particle size, high molecular weight, high uniformity, and high drug encapsulation efficiency, achieving the substitution of non-reactive surfactants with reactive surfactants. A coating can be prepared using the above-mentioned polymer-loaded drug-eluting nanoparticles. The coating can be further used to prepare sustained-release antibacterial surface film materials through cross-linking film formation, exhibiting good mechanical properties, excellent chemical resistance, and high safety. This invention can be widely applied to various environmental and material surfaces, including but not limited to surface modification of instruments and building materials in residential and medical environments, thereby achieving a long-lasting antibacterial effect.

The invention discloses a production process of lipid nanoparticles entrapped with weak-acid and weak-hydrophobicity small molecule drugs, which comprises the following steps: S1, preparing a water phase and an organic phase, the organic phase comprising a lipid organic phase and a drug organic phase; s2, under an ultrasonic condition, successively mixing the water phase, the drug organic phase and the lipid organic phase in a microreactor through a microfluidic technology to form lipid nanoparticles, so as to obtain a crude sample containing the lipid nanoparticles; s3, diluting the crude sample by using a PBS (Phosphate Buffer Solution), and standing to obtain a sample diluent; s4, the sample diluent is subjected to ultrafiltration concentration, a concentrated sample is obtained, and a lipid nanoparticle product loaded with the medicine components is obtained. By adjusting the mixing time of the lipid component phase and other two-phase solutions, the drug precipitation rate and the lipid component precipitation rate are flexibly regulated and controlled, the drug encapsulation efficiency is effectively improved, and industrial production is facilitated.

The present invention relates to a continuous ultrasonic reactor capable of performing continuous chemical reactions using multiple ultrasonic generators installed in parallel. The reactor body includes a reactant inlet and a product outlet, and the ultrasonic generators are uniformly arranged inside the reactor to induce mixing of reactants and the generation of free radicals through ultrasonic cavitation. As a result, the reaction can be effectively initiated without the use of a chemical initiator, and the reaction speed and efficiency are significantly improved. In addition, a cooling jacket is installed on the exterior of the reactor to stably maintain the reaction temperature, thereby ensuring uniformity of reaction conditions. The operating conditions of the ultrasonic generators can be adjusted via a control panel, allowing for flexible application to various chemical reaction processes. The present invention can be utilized in high-efficiency chemical processes such as polymer polymerization, nanoparticle synthesis, and drug encapsulation, and is an innovative technology that simultaneously provides energy efficiency and eco-friendliness.

This invention discloses a method for preparing avermectin nanoparticles supported on zein-sodium lignin sulfonate, and its applications. The preparation method involves dissolving avermectin and zein in an organic solvent to form a solution (stream 1), and dissolving sodium lignin sulfonate or modified sodium lignin sulfonate in deionized water to form a solution (stream 2). Both streams are simultaneously injected into a dual-channel confined counter-current mixer for rapid mixing. The resulting nanoparticle suspension is then collected, completing the preparation process. This invention utilizes the compatibility of hydrophobic zein with avermectin, combined with the self-assembly properties of zein and the use of sodium lignin sulfonate or modified sodium lignin sulfonate as a stabilizer, to prepare avermectin nanoparticles with high drug encapsulation efficiency and excellent drug release performance. Furthermore, these nanoparticles exhibit excellent resistance to UV photodegradation, effectively reducing the photodegradation of avermectin. The method is simple, rapid, and easy to control.

The invention discloses papaverine hydrochloride sustained-release microspheres for injection and a preparation method of the papaverine hydrochloride sustained-release microspheres, and relates to the technical field of pharmaceutical preparations. The sustained-release microsphere comprises an active component, a composite carrier, a composite stabilizer and a freeze-drying protective agent. The composite carrier is a compound formed by grafting a polylactic acid-glycolic acid copolymer and hyaluronic acid, the composite stabilizer is a mixture of an antioxidant and an amino acid compound, the freeze-drying protective agent is a mixture of polyol and saccharides, and the surface of the microsphere is provided with a hydrophilic-hydrophobic gradient coating composed of a hydrophobic layer, an amphiphilic layer and a hydrophilic layer. The preparation method comprises the steps of primary emulsion preparation, multiple emulsion preparation, step-by-step curing, surface modification and freeze-drying treatment, and adopts the processes of gradient emulsification, step-by-step curing, layer-by-layer grafting, gradient cooling and segmented sublimation. According to the technical scheme, the drug encapsulation efficiency and the drug loading capacity are effectively improved, the burst release rate is reduced, long-acting stable slow release is realized, the storage stability and the biocompatibility are enhanced, and a safe and effective drug administration choice is provided for treatment of ischemic diseases.

The invention discloses lipidosome, a medicine lipidosome compound and a preparation method and application of the medicine lipidosome compound. The liposome comprises the following components in parts by mass: 10-65 parts of saturated phospholipid; 25 to 75 parts of unsaturated phospholipid; 0.5 to 15 parts of a trigger lipid; the trigger lipid is sphingolipid and / or cholesterol; the mass ratio of the saturated phospholipid to the unsaturated phospholipid is (0.20-2.50): 1. When the lipidosome is used for drug encapsulation, high encapsulation efficiency can be guaranteed, high activity of drugs can be maintained, the lipidosome can be stably stored, and a universal carrier is provided for drugs with different physicochemical properties (especially highly hydrophilic drugs, such as protein drugs and nucleic acid drugs).

The invention discloses a deep learning-based lamp inspection data monitoring system after drug encapsulation and sterilization, and the system comprises the steps: carrying out the cumulative calculation of a determined intensity change sequence through a dose integration algorithm, fusing the position coordinates and the stay time information, and obtaining the actual accepted dose value of each drug; if the obtained actual accepted dose value is lower than the preset sterilization threshold value, triggering an environment factor adjustment module to simulate the three-dimensional attenuation atlas again, and judging whether the adjusted three-dimensional attenuation atlas improves the coverage rate of a low-intensity area or not; obtaining optimized intensity distribution data by comparing the difference between the adjusted three-dimensional attenuation atlas and the original atlas, and determining the expected dose increase amplitude under the drug re-path; updating input parameters of a dose integration algorithm according to the determined lifting amplitude, and recalculating dose values of all the medicines to obtain an overall sterilization consistency index of the batch; if yes, outputting a personalized evaluation report, and judging that the sterilization state of each medicine meets the requirement.

The invention relates to the technical field of progesterone sustained-release nanoparticle production, in particular to a progesterone sustained-release nanoparticle which comprises progesterone and further comprises solid lipid and liquid lipid according to the formula ratio of 1: 1.4: 1.2: 0.8. A preparation method of the progesterone sustained-release nanoparticle comprises raw material preparation of progesterone, solid lipid and liquid lipid and melt emulsification. The prepared progesterone lipid nanoparticles have high drug entrapment efficiency which can reach 77.48% at most, and have obvious drug sustained and controlled release performance, although the particle size of the nanoparticles is increased along with the increase of the content of liquid lipid-oleic acid in the lipid nanoparticles, the drug entrapment efficiency is improved, the in-vitro release of the drug is accelerated, and the progesterone lipid nanoparticles have good application prospects. According to the progesterone nanostructure lipid carrier, the drug content in the preparation process of the nanoparticles is improved, the drug encapsulation efficiency of the prepared progesterone nanostructure lipid carrier is reduced, but the drug loading capacity of the nanoparticles can be improved, and when the dosage reaches 20%, the drug loading capacity of the nanoparticles can reach 11.57%.

The invention relates to the technical field of protein drugs, in particular to a human ferritin light chain variant and a glycosylation modified human ferritin light chain variant. According to the invention, an N-glycan modification sequence is introduced at a proper position, and the obtained human ferritin light chain variant can be used for constructing a glycosylation modified human ferritin light chain. The glycosylation-modified human ferritin light chain has good stability and protease degradation resistance, the immunogenicity is remarkably reduced, and meanwhile, a natural cavity structure is reserved, so that the glycosylation-modified human ferritin light chain can be used as a drug carrier to realize good embedding of drugs.

The present invention discloses a non-linear PEGylated lipid, including the structure represented by the Formula (1); wherein, B1 and B2 are linking bonds or alkylene groups; L1 and L2 are linking bonds or divalent linking groups; Lx, Y, and Ld are divalent linking groups; R1 and R2 are C4-50 hydrocarbon groups or C4-50 residues of hydrocarbon derivative containing 1-4 heteroatoms; X is —CH< orn1, n2, and n3 are integers in the range of 4-250; T is a terminal group. Compared with linear PEGylated lipids, the non-linear PEGylated lipid provided herein can realize better protective effects toward the modified LNPs. The lipid pharmaceutical composition of the present invention exhibits high efficiency of drug encapsulation, appropriate particle size, non-toxicity, and good stability in serum. The LNP-nucleic acid pharmaceutical composition of the present invention demonstrates an excellent ability to complex with nucleic acids and shows high transfection activity.

The present invention relates to the field of liposome technology, and more specifically, to a lipid composition for preparing liposomes and a method for preparing the same. The lipid composition is a lyophilized powder comprising phospholipids and cholesterol in a proportion consistent with liposome preparation, wherein at least a portion of the cholesterol is present in an amorphous form. The lipid composition has excellent hydration capacity, thereby effectively simplifying the liposome preparation process and shortening the preparation time. Since the lipid composition can be fully hydrated, the formed liposomes can be ensured to have a correct bilayer structure, thereby ensuring a reliable drug encapsulation rate and improving the stability and reliability of the process.

The invention relates to an anti-inflammatory and lipid-lowering-based nano preparation for treating fatty liver and a preparation method of the nano preparation. Galactose modified polyethylene glycol-polylactic acid-glycolic acid copolymer (PEG-PLGA) is used as a targeting carrier, and a lipid-lowering drug fenofibrate and an anti-inflammatory drug curcumin are co-loaded; the particle size of the nano preparation is 150-200nm, and the drug encapsulation efficiency is greater than or equal to 85%. Galactose modified PEG-PLGA is adopted as a carrier, galactose can be specifically combined with an asialoglycoprotein receptor (ASGPR) specifically expressed on the surface of liver cells, active targeting of the liver is achieved, the drug enrichment amount of the liver lesion position is remarkably increased, meanwhile, accumulation of drugs in extrahepatic tissue is reduced, extrahepatic toxicity is effectively reduced, and the drug delivery effect is improved. According to the present invention, the anti-inflammatory drug curcumin and the fenofibrate are combined, such that the biological safety of the preparation is improved, the lipid lowering drug fenofibrate and the anti-inflammatory drug curcumin are innovatively co-loaded, and the fenofibrate and the anti-inflammatory drug curcumin form the synergistic effect system: fenofibrate can activate peroxisome proliferator-activated receptor alpha (PPAR alpha), promote liver lipid catabolism, and reduce lipid deposition;

The application discloses a preparation method and application of an anti-adhesion nano composite drug delivery system, relates to the technical field of adhesives, and discloses the following technical scheme: polyacrylamide and aldehyde functionalized starch with a preset mass ratio are taken, different amounts of zeolite imidazolate framework materials are added after mixing, and then the mixture after mixing is ground and sieved to obtain the anti-adhesion nano composite drug delivery system. The application can be used as a peritoneal tumor local drug delivery system, has high drug encapsulation efficiency and drug loading rate, can release antitumor drugs in tumor tissues specifically, continuously and stably through a tumor acid microenvironment, prolongs the exposure time of the drugs, improves the curative effect of the drugs, reduces the side effects of chemotherapy, can reshape an immune microenvironment, has a good killing effect on tumor cells, and has no systemic toxicity; meanwhile, the gel powder forms a physical barrier on a surgical wound after being changed into a gel by water, so that abdominal cavity adhesion caused by surgical trauma and chemotherapy can be reduced.

A platform of drug delivery based on self-lysis of ECN, a constructing method, and use of the platform are provided. The platform of drug delivery comprises ECN, a Pvhb-GST-PhiX174E circuit genetically introduced into ECN, and a drug encapsulation material. When the platform is used as an anti-cancer drug carrier, the platform delivers a high concentration of chemotherapeutic drugs to a tumor site. Additionally, through the Pvhb-GST-PhiX174E circuit, ECN is induced to lyse in response to tumor microenvironment signals, leading to cell death in the tumor region and enhancing ECN's biosafety in vivo. Furthermore, ECN within the platform of drug delivery based on self-lysis of ECN serves as an immune adjuvant, stimulates the immune cell activity in the tumor site, triggers acute inflammation, and strengthens the anti-tumor effect, thereby achieving multi-modal anti-tumor therapy through live-cell, chemotherapy, and immunotherapy.

This application belongs to the field of nanomedicine technology, and particularly relates to an artificially evolved protein cage nanomedicine, its preparation method, and its application. The artificially evolved protein cage nanomedicine provided by this application includes an artificially evolved protein cage and a nucleic acid-based biomolecular drug. The artificially evolved protein cage is artificially obtained by an artificial evolution system from a 240-polymer nanoprotein cage C27-A with PDB number 6NJ8. The amino acid sequence of the protein subunit of the artificially evolved protein cage is shown in SEQ ID NO.1. The artificially evolved protein cage can efficiently encapsulate nucleic acid-based biomolecular drugs and has advantages such as high protein yield, good stability, good tumor efficacy, and excellent safety. It can solve the technical problem of low drug encapsulation efficiency in existing protein cage nanomedicines.

A pharmaceutical crystal having low water solubility, a preparation method therefor, and the use thereof. A crystal form I of pamoate of a compound Z has characteristic diffraction peaks at the diffraction angles 2θ of 9.9±0.2°, 10.7±0.2°, 12.1±0.2°, 14.9±0.2°, 17.3±0.2°, 19.4±0.2°, 20.7±0.2° and 23.1±0.2°. Compared with amorphous pamoate of the compound Z, said crystal has good stability, is free of polymorphic transformation, does not involve obvious increases of related substances, and has a low solubility. A production process therefor is simple and only uses water as a solvent in the whole process without the need of using an organic solvent. Using the crystal form I of pamoate of the compound Z for preparing a long-acting sustained-releasing pharmaceutical composition for Parkinson's disease can achieve a high drug encapsulation ratio and low burst release, and enables drug release of the composition in vivo to last for over two weeks, so that the frequency of drug administration to patients can be reduced, and the medication compliance is improved.

A liposome of a nitrogen-containing heterocyclic compound comprises the following components: a nitrogen-containing heterocyclic compound as shown in compound 3 below and a lipid component. The liposomes of the present invention satisfy one or more of the following advantages: (1) small particle size and uniform distribution; (2) high API content; (3) high drug encapsulation efficiency; (4) good stability; (5) good antitumor activity; (6) good safety; and (7) long-lasting effect.

The invention relates to the technical field of biological detection, and particularly discloses a detection method of a bionic nano-carrier system based on a GPC3 engineering macrophage membrane in liver cancer treatment, and the detection method comprises the steps of S1, nanoparticle preparation, S2, drug encapsulation, S3, macrophage membrane MM preparation, S4, nanoparticle and macrophage membrane combination, S5, GPC3 targeted modification, and S6, in-vitro cell experimental verification. Through modification of the GPC3 targeting peptide, the nanoparticles can specifically target liver cancer cells, so that the targeting property of liver cancer treatment is greatly improved, and damage to normal tissues is reduced; the use of the macrophage membrane effectively avoids the phagocytosis of an immune system, enhances the circulation time and stability of the drug in vivo, improves the immunotherapy effect, and can significantly induce ferroptosis of liver cancer cells in combination with sorafenib (Sor) and astragaloside IV (As), thereby providing a novel treatment strategy and improving the treatment effect of liver cancer.

The present disclosure provides injectable microsphere formulations capable of controlled long-term sustained release. The disclosed microsphere formulations exhibit zero order release of the active agent over a predetermined period of time. Methods of making the microsphere formulations and methods of using the same are also disclosed. The disclosed method can easily enlarge scale while maintaining high drug encapsulation efficiency.

The invention relates to the technical field of pharmaceutical preparations, and discloses a doxorubicin and cyclophosphamide liposome compound injection which is prepared from doxorubicin hydrochloride, cyclophosphamide, hydrogenated soybean phosphatidylcholine, cholesterol, polyethylene glycol derivative phospholipid, anhydrous magnesium sulfate, L-arginine and a sucrose octasulfate ammonium solution. Magnesium ions introduced into an inner water phase participate in competitive binding, doxorubicin and sucrose octasulfate are induced to form a loose co-precipitation structure with lattice defects, hydrophilic cyclophosphamide is physically filled and cured by using micro gaps, and efficient encapsulation of non-gradient dependent drugs is realized. Meanwhile, an in-situ pH buffer system is constructed by using L-arginine, protons generated in a drug loading process are neutralized, an internal water phase is maintained in a neutral environment, and acid-catalyzed hydrolysis of cyclophosphamide is effectively inhibited. According to the invention, the double-drug encapsulation efficiency and storage stability of the compound liposome are obviously improved.

A preparation of PEGylated solid lipid core nanocarriers (SLN) is loaded with at least one drug for delivery to a subject. SLNs having a small size, neutral charge, and high drug encapsulation efficiency are formed. PEGylation improves SLN permeability without hindering cellular uptake, particularly permeability of nasal mucous for intranasal delivery. PEGylated SLNs are suitable for intranasal, inhaled, oral or injected drug delivery. Exemplary formulations include a combined antiretroviral therapy (cART) designed to cross the blood-brain barrier and treat neuroAIDS.

This invention relates to a method for preparing resveratrol nanoparticles, belonging to the field of traditional Chinese medicine technology. Addressing the problems of low oral bioavailability and lack of colonic targeting of resveratrol, this invention provides a nanoparticle formulation composed of resveratrol, zein, and xylan. The formulation is prepared by dissolving resveratrol and zein in an organic phase, adding them dropwise to an aqueous xylan phase, and then evaporating the organic solvent. This invention utilizes the hydrophobic effect of zein to improve drug encapsulation efficiency and leverages the colonic degradation characteristics and anti-inflammatory activity of xylan to achieve synergistic effects, enabling precise release of resveratrol at sites of intestinal inflammation.

The application discloses a pre-gelatinized starch / calcium-containing mineral-berberine compound and a preparation method and application thereof, and comprises the following steps: mixing an organic acid salt or an inorganic acid salt, starch and water, and performing microwave treatment to obtain a starch-salt colloid solution; mixing calcium salt, berberine and ethanol to obtain an ethanol solution containing berberine and calcium salt; adding the starch-salt colloid solution into the ethanol solution containing berberine and calcium salt, stirring and reacting, performing retrogradation treatment, centrifuging to obtain a precipitate, and drying to obtain the compound. The application combines the starch "gelatinization-retrogradation" mechanism and the calcium-containing mineral biomimetic mineralization method, completes the encapsulation of berberine, and prepares the berberine compound with the pre-gelatinized starch / calcium-containing mineral as a drug delivery system, so that the berberine compound has a high drug encapsulation rate, the gastrointestinal stability of the berberine is remarkably improved, a good sustained-release effect is generated, the bioavailability of the berberine is improved, and a new way is provided for the clinical application of the berberine.

The application discloses a preparation method of Janus water-based microgel and belongs to the technical field of microgel. The Janus water-based microgel is successfully prepared based on vortex oscillation into emulsion and ultraviolet light irradiation. 1. Solution preparation: polymerization monomers / crosslinking agent / initiator are weighed, and an oil phase solution containing Span 80 surfactant is prepared; an ATPS aqueous solution is prepared; 2. Preparation of Janus emulsion droplets; 3. Preparation of Janus water-based microgel; 4. Washing of Janus water-based microgel. The oil phase and surfactant used in the application are cheap and easy to obtain, the preparation method is simple, and through the change of the components of the double water phase and the type of the surfactant, Janus water-based microgels with different morphologies can be obtained. The Janus water-based microgel prepared in the application is expected to be used for drug encapsulation and treatment.

Methods for intranasal delivery of a GLP-1 (glucagon-like peptide-1) drug, such as tirzepatide (TZP), using a formulation of the drug encapsulated in poly(lactic-co-glycolic acid) or poly(caprolactone) nanoparticles optionally coated with chitosan and / or polyethylenimine-grafted chitosan at an optimized condition for surface charge change and particle size control are described. The disclosed intranasal formulations successfully provides dosing-dependent body fat loss in mice, showing a significant therapeutic effect.

The invention belongs to the field of pharmaceutical preparations, and particularly relates to a pH-sensitive epirubicin hydrochloride liposome and a preparation method thereof. According to the invention, ammonium dihydrogen phosphate is adopted as a pH gradient establishment substance, active drug loading is carried out on epirubicin hydrochloride, and high drug encapsulation efficiency and good drug release difference under different pH conditions are achieved. Within the pH range of the tumor internal environment, the release rate is higher, the release is more thorough, and the quick release of the drug at the tumor tissue part is more facilitated. In the pH range of normal tissues, the liposome is slowly released, and the lymphatic system is facilitated to remove the liposome, so that the treatment effect of tumor tissues is enhanced, adverse reactions such as cardiotoxicity are reduced, and the purposes of reducing toxicity and improving efficiency are achieved.

The application provides a kind of double-loading microcapsule containing pyraclostrobin and brassinolide and its preparation method and application, and the double-loading microcapsule includes core material and wall material, and the wall material covers the core material;The core material includes pyraclostrobin and 24-epibrassinolide, and the wall material includes polylactic acid-hydroxyacetic acid copolymer and hydroxypropyl methyl cellulose phthalate, and the mass ratio of polylactic acid-hydroxyacetic acid copolymer, hydroxypropyl methyl cellulose phthalate is (40-50):(90-100);The application uses polylactic acid-hydroxyacetic acid copolymer and hydroxypropyl methyl cellulose phthalate with suitable mass ratio as wall material, combined with the preferred preparation method, so that the drug loading of microcapsule and the drug encapsulation efficiency are high, the drug diffusion rate can be effectively controlled, the sustained-release effect is good, and the double-loading microcapsule particle size is suitable, the effective period is long, and the preparation method is simple, so that the prepared double-loading microcapsule particle size distribution is uniform, without damage and coating phenomenon.